Navigation Links
Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
Date:12/16/2009

ll differentiation and cell survival. KRX-0401 is currently in a Phase 3 trial, under Special Protocol Assessment (SPA), in multiple myeloma, and in Phase 2 clinical development for several other tumor types. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, and Keryx is in the process of finalizing the U.S. Phase 3 program for Zerenex in consultation with the FDA. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for KRX-0401 (perifosine), may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete clinical trials for KRX-0401; the risk that the data (both safety and efficacy) from the Phase 3 trial will not coincide with the data analyses from the Phase 1 / 2 clinical trial previously reported by the Company; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... BOSTON , January 23, 2015 ... company, is delighted to announce that the Malcolm Campbell ... Miles Congreve (Vice President of Chemistry), Fiona Marshall ... (Chief Executive Officer and co-founder) for the seminal contributions ...
(Date:1/22/2015)... Inc. (NASDAQ: UPI ), a medical device company ... treat voiding dysfunctions, today reported financial results for the ... Global revenue for the Company,s Urgent ®  PC Neuromodulation ... revenue record, as compared to $3.9 million in the ...
(Date:1/22/2015)... , Jan. 22, 2015  Bio-Techne Corporation (NASDAQ: ... the first member of the new Simple Plex platform ... This launch represents the re-branding of the previously acquired ... Plex platform is a transformative immunoassay technology which integrates ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3
... 21, 2012 As the diverse areas of ... so too must medical technologies reform to solve ... market drivers and restraints into an interpretable roadmap, ... Enabling Efficient and Outcomes-Oriented Healthcare Delivery, 2010 to ...
... HAMPTON, N.J., March 21, 2012 Ikaria, Inc., a critical ... critically ill patients, today announced that the Center for ... branch of the U.S. Food and Drug Administration (FDA) has ... with three additional respiratory care devices. The INOMAX DS and ...
Cached Medicine Technology:Frost & Sullivan's Advanced Medical Technologies Research Tracks Opportunities in Markets Influenced by Dynamic Care Pathways 2Frost & Sullivan's Advanced Medical Technologies Research Tracks Opportunities in Markets Influenced by Dynamic Care Pathways 3FDA Clears Expanded Compatibility for INOMAX® Drug-Delivery Systems 2FDA Clears Expanded Compatibility for INOMAX® Drug-Delivery Systems 3
(Date:1/22/2015)... A new white paper by The ... in the long-term care environment as well as provides ... The paper, “The Power of Person-Centeredness in Long-Term Care: ... of the patient, resident and family experience in long-term ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of Cruz ... has treated just about every type of injury that can result ... those same twenty-plus years, the team at Doctors on Liens ... best possible doctor. With the combined breadth of experience ...
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 ... of Sports Medicine flagship journal Medicine & Science ... L-Citrulline before exercise may help reduce gastrointestinal (GI) ... 1 , Participants in the double-blind, placebo-controlled ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 IsoComforter, Inc. has ... machine with patented IsoTube design to treat specific body parts ... the most progressive and easy to use patented cold therapy ... and sports related orthopedic and muscle injuries. IsoComforter has ...
(Date:1/22/2015)... Mass. (PRWEB) January 22, 2015 EBSCO ... (AMA) are expanding their relationship in an effort to ... around the world. While EBSCO has long made AMA journals ... a sales agent for The JAMA Network. , ...
Breaking Medicine News(10 mins):Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... , ... Biomedical,s new facility will support all the manufacturing and distribution operations for the company’s ... , ... 13, 2010 -- Blue Ocean Biomedical announced the opening of a new manufacturing facility ...
... ... cigarettes. , ... 2010 -- The Primax Electronic Cigarette System is now available from Primevapor.com., , ,Primevapor has ... flavor cartridges. These cartridges not only produce more flavor and more vapor, but use US ...
... not as interested in information on lifestyle changes , FRIDAY, ... the recent deluge of scientific discoveries of links between specific ... healthy people with something they don,t need: an excuse for ... people are going to use genetics as a way to ...
... Leading Gulf Coast medical centers, universities and public health ... a consortium to improve community disaster readiness and recovery ... environmental health. The consortium, known as SECURE ... funded through a two-year, $4 million grant from the ...
... When applied to HIV care, the community-based model ... on virologic outcomes, but significantly improves patient survival. ... Hopkins Bloomberg School of Public Health, in collaboration ... Africa, who conducted the first randomized controlled trial ...
... new strain of bacteria that can produce non-toxic, comparatively ... or PAHs environmental pollutants that are one of ... of its unique characteristics, this new bacterial strain could ... the massive Gulf Coast oil spill, scientists say. ...
Cached Medicine News:Health News:Electronic Cigarettes Are Better Than Ever 2Health News:Least Healthy More Apt to Think Genes Explain Disease Risk 2Health News:Least Healthy More Apt to Think Genes Explain Disease Risk 3Health News:Least Healthy More Apt to Think Genes Explain Disease Risk 4Health News:Research alliance aims to help vulnerable communities cope with disaster 2Health News:Research alliance aims to help vulnerable communities cope with disaster 3Health News:Research alliance aims to help vulnerable communities cope with disaster 4Health News:Directly observed HIV treatment by patient-nominated treatment supporter improves survival 2Health News:New strain of bacteria discovered that could aid in oil spill, other environmental cleanup 2Health News:New strain of bacteria discovered that could aid in oil spill, other environmental cleanup 3
... Sonomed-315 is intended for visualization of the ... midline shifts in the brain, evaluation of ... to use, the Sonomed-315 offers quick and ... allows to identify the anatomic structures of ...
... Ateles is a scaleable device ... volume of platelet plasma or ... or buffy coat must be ... and techniques. Starting volume and ...
The Ultrafoam Collagen Sponge is indicated in all surgical procedures as an adjunct to hemostasis when control by ligature or conventional procedures are ineffective or impractical....
... design is based upon the physiological ... spinal motion segment unit. Kinematics and ... the biomechanical and anatomical aspects of ... Three implant components utilizing proven implant ...
Medicine Products: